nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2016 | Original Article – Cancer Research

Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification

verfasst von: Midea Gierke, Jan Sperveslage, David Schwab, Rudi Beschorner, Martin Ebinger, Martin U. Schuhmann, Jens Schittenhelm

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

Gliomas are the leading cause of cancer-related morbidity in children and comprise a clinical, histological and molecular heterogenous group of CNS tumors. Appropriate treatment of these tumors relies on correct classification into tumor types and malignancy grades.

Methods

We examined 170 (0–18 years) pediatric and 131 (19–35 years) young adult brain tumors including pilocytic astrocytomas (PAs), pilomyxoid astrocytomas (PMAs), diffuse astrocytomas (DAs), gangliogliomas, dysembryoplastic neuroepithelial tumors (DNTs) and pleomorphic xanthoastrocytomas (PXAs) for IDH1 and BRAF mutation/BRAF fusion gene status. The obtained data were compared to results in 464 (<35 years) adult brain tumors. In 32 tumors with an oligodendroglial or mixed glioma differentiation, additionally the LOH1p/19q status was determined.

Results

By combining immunohistochemistry and molecular methods, IDH1/2 mutations were observed in 6 pediatric, 35 young adult and 43 adult tumors of the astrocytic/oligodendroglial lineage. BRAF V600E mutations (20 pediatric, 7 young adults and 2 adults) were found mostly in gangliogliomas, PXAs, few astrocytomas and few DNTs. Except for one DA case, BRAF fusions (35 pediatric, 8 young adults and 2 adults) were restricted to PA and PMA and associated with age and infratentorial location. All mutations were mutually exclusive and always present in the primary tumor. Two-thirds of all pediatric samples harbored one of the three examined mutations.

Conclusion

Combination of IDH1-R132, BRAF V600 and KIAA1549–BRAF fusion analysis is therefore a useful tool to increase diagnostic accuracy in pediatric gliomas.

Antonelli M, Badiali M, Moi L, Buttarelli FR, Baldi C, Massimino M, Sanson M, Giangaspero F (2015) KIAA1549:BRAF fusion gene in pediatric brain tumors of various histogenesis. Pediatr Blood Cancer 62(4):724–727PubMedCrossRef

Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, Guerrera ML, Lucioni M, Tenore A, Merli M, Rizzi S, Morello L, Cavalloni C, Da Vià MC, Paulli M, Cazzola M (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119:188–191PubMedCrossRef

Badiali M, Gleize V, Paris S, Moi L, Elhouadani S, Arcella A, Morace R, Antonelli M, Buttarelli FR, Figarella-Branger D, Kim YH, Ohgaki H, Mokhtari K, Sanson M, Giangaspero F (2012) KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol 22:841–847PubMedCrossRef

Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, Guo D, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley PE (2014) Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61:1173–1179PubMedPubMedCentralCrossRef

Buccoliero AM, Castiglione F, Degl’Innocenti DR, Gheri CF, Genitori L, Taddei GL (2012) IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value? Fetal Pediatr Pathol 31:278–282PubMedCrossRef

Bullock M, O’Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ (2012) Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 19:779–784PubMedCrossRef

Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19PubMedCrossRef

Chappé C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23:574–583PubMedCrossRef

Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN (2013) BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 31:e233–e236PubMedCrossRef

Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Côté JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF (2013) Detection of BRAF p. V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15:94–100PubMedCrossRef

Cruz GR, Dias Oliveira I, Moraes L, Del Giudice Paniago M, de Seixas Alves MT, Capellano AM, Saba-Silva N, Cavalheiro S, Cerutti JM, Toledo SR (2014) Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J Neurooncol 117:235–242PubMedCrossRef

Daumas-Duport C, Varlet P, Bacha S, Beuvon F, Cervera-Pierot P, Chodkiewicz JP (1999) Dysembryoplastic neuroepithelial tumors: nonspecific histological forms—a study of 40 cases. J Neurooncol 41:267–280PubMedCrossRef

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef

Dimitriadis E, Alexiou GA, Tsotsou P, Simeonidi E, Stefanaki K, Patereli A, Prodromou N, Pandis N (2013) BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors. J Neurooncol 113:353–358PubMedCrossRef

Donson AM, Kleinschmidt-Demasters BK, Aisner DL, Bemis LT, Birks DK, Levy JM, Smith AA, Handler MH, Foreman NK, Rush SZ (2014) Pediatric brainstem gangliogliomas show BRAFV600E mutation in a high percentage of cases. Brain Pathol 24:173–183PubMedPubMedCentralCrossRef

Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncology 12:621–630PubMedPubMedCentralCrossRef

Freeman CR, Farmer JP, Montes J (1998) Low-grade astrocytomas in children: evolving management strategies. Int J Radiat Oncol Biol Phys 41:979–987PubMedCrossRef

Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T (2013) H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. Am J Clin Pathol 139:345–349PubMedCrossRef

Gilles FH, Tavaré CJ, Becker LE, Burger PC, Yates AJ, Pollack IF, Finlay JL (2008) Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study. Pediatr Dev Pathol 11:108–117PubMedCrossRef

Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A (2005) Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64:10–14PubMed

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474PubMedCrossRef

Hasselblatt M, Riesmeier B, Lechtape B, Brentrup A, Stummer W, Albert FK, Sepehrnia A, Ebel H, Gerss J, Paulus W (2011) BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol 37:803–806PubMedCrossRef

Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF (2010) Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 119:641–649PubMedCrossRef

Ida CM, Lambert SR, Rodriguez FJ, Voss JS, Mc Cann BE, Seys AR, Halling KC, Collins VP, Giannini C (2012) BRAF alterations are frequent in cerebellar low-grade astrocytomas with diffuse growth pattern. J Neuropathol Exp Neurol 71:631–639PubMedCrossRef

Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, Giannini C (2013) Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun 1:20PubMedPubMedCentralCrossRef

Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, von Deimling A, Emile JF, Hofman P (2013) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24:742–748PubMedCrossRef

Jones DT, Kocialkowski S, Liu L, Pearson DM, Pearson DM, Bäcklund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673–8677PubMedPubMedCentralCrossRef

Kim YH, Nonoguchi N, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Mariani L, Giangaspero F, Tanaka Y, Nakazato Y, Vital A, Mittelbronn M, Perry A, Ohgaki H (2012) Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol 22:834–840PubMedCrossRef

Koelsche C, Sahm F, Wöhrer A, Jeibmann A, Schittenhelm J, Kohlhof P, Preusser M, Romeike B, Dohmen-Scheufler H, Hartmann C, Mittelbronn M, Becker A, von Deimling A, Capper D (2014) BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol 24:221–229PubMedCrossRef

Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118:401–405PubMedCrossRef

Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129:669–678PubMedCrossRef

Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, Suri V, Sharma MC, Suri A, Sarkar C (2015) Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet 208:91–95PubMedCrossRef

Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, Hartmann C, von Deimling A (2010) PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20:298–300PubMedCrossRef

Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS (2008) BRAF(E600) in benign and malignant human tumours. Oncogene 27:877–895PubMedCrossRef

Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EJ, Zhou T, Jakacki RI, Children’s Oncology Group (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Childs Nerv Syst 27:87–94PubMedPubMedCentralCrossRef

Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120:567–584PubMedPubMedCentralCrossRef

Rodriguez FJ, Schniederjan MJ, Nicolaides T, Tihan T, Burger PC, Perry A (2015) High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol 129:609–610PubMedPubMedCentralCrossRef

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405PubMedCrossRef

Schittenhelm J, Mittelbronn M, Meyermann R, Melms A, Tatagiba M, Capper D (2011) Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma. Acta Neuropathol 122:651–652PubMedCrossRef

Schmidt Y, Kleinschmidt-DeMasters BK, Aisner DL, Lillehei KO, Damek D (2013) Anaplastic PXA in adults: case series with clinicopathologic and molecular features. J Neurooncol 111:59–69PubMedPubMedCentralCrossRef

Sievert AJ, Fisher MJ (2009) Pediatric low-grade gliomas. J Child Neurol 24:1397–1408PubMedPubMedCentralCrossRef

Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC (2013) Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci USA 110:5957–5962PubMedPubMedCentralCrossRef

Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K (2007) The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 46:242–248PubMedCrossRef

Thom M, Toma A, An S et al (2011) One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol 70:859–878PubMedCrossRef

Vannemreddy PS, Kanner AM, Smith MC, Rossi M, Wallace D, Vannemreddy SN, Byrne RW (2013) Chronic epilepsy due to low grade temporal lobe tumors and due to hippocampal sclerosis: do they differ in post-surgical outcome? J Neurooncol 115:225–231PubMedCrossRef

Wallace D, Ruban D, Kanner A, Smith M, Pitelka L, Stein J, Vannemreddy PS, Whisler WW, Byrne RW (2013) Temporal lobe gangliogliomas associated with chronic epilepsy: long-term surgical outcomes. Clin Neurol Neurosurg 115:472–476PubMedCrossRef

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome Project (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867PubMedCrossRef

Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875–885PubMedCrossRef

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedPubMedCentralCrossRef

Titel: Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification
verfasst von: Midea Gierke
Jan Sperveslage
David Schwab
Rudi Beschorner
Martin Ebinger
Martin U. Schuhmann
Jens Schittenhelm
Publikationsdatum: 01.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2006-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing’s sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity

Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy

Replication analysis confirms the association of several variants with acute myeloid leukemia in Chinese population

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie